Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Pre-Mkt 06-30 07:52:15 EDT

23.85

+0.95

+4.15%

盘前23.87

+0.02+0.08%

07:00 EDT

High24.03	Low22.97	Vol2.75M
Open23.16	D1 Closing22.90	Amplitude4.63%
Mkt Cap2.47B	Tradable Cap2.06B	Total Shares103.41M
T/O65.19M	T/O Rate3.18%	Tradable Shares86.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":23.85,"timestamp":1782763200000,"preClose":22.9,"halted":0,"volume":2746939,"hourTrading":{"tag":"盘前","latestPrice":23.87,"preClose":23.85,"latestTime":"07:00 EDT","volume":1015,"amount":24229.636445,"timestamp":1782817200165,"change":0.02,"changeRate":0.000839,"amplitude":0.055346},"delay":0,"changeRate":0.041484716157205365,"floatShares":86361800,"shares":103405813,"eps":-3.165026,"marketStatus":"Pre-Mkt","change":0.95,"latestTime":"06-30 07:52:15 EDT","open":23.16,"high":24.03,"low":22.97,"amount":65194004.282992,"amplitude":0.046288,"askPrice":24.25,"askSize":17,"bidPrice":23.6,"bidSize":6,"shortable":3,"etf":0,"ttmEps":-3.165026,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782826200000},"marketStatusCode":1,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":23.85,"preHourTrading":{"tag":"盘前","latestPrice":23.87,"preClose":23.85,"latestTime":"07:00 EDT","volume":1015,"amount":24229.636445,"timestamp":1782817200165,"change":0.02,"changeRate":0.000839,"amplitude":0.055346},"postHourTrading":{"tag":"盘后","latestPrice":23.85,"preClose":23.85,"latestTime":"19:04 EDT","volume":366583,"amount":8743006.93,"timestamp":1782774253770,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7300150746441056,"impliedVol":0.7302,"impliedVolPercentile":0.532},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"2647488379","title":"Nurix Therapeutics assumed with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2647488379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647488379?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:00","pubTimestamp":1782734416,"startTime":"0","endTime":"0","summary":"Oppenheimer assumed coverage of Nurix Therapeutics (NRIX) with an Outperform rating and $28 price target The firm likes the Nurix setup that mainly...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-assumed-with-an-outperform-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647634009","title":"Nurix Therapeutics (NRIX) Is Up 30.5% After Landmark Roche BTK Degrader Collaboration - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2647634009","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647634009?lang=en_us&edition=fundamental","pubTime":"2026-06-29 11:16","pubTimestamp":1782703000,"startTime":"0","endTime":"0","summary":"Earlier this year, Roche and Nurix Therapeutics announced a collaboration to co-develop and co-commercialize bexobrutideg (NX-5948), an oral Bruton’s tyrosine kinase degrader for blood cancers and other potential indications, with Nurix eligible for a US$700 million upfront payment and up to US$2.30 billion in milestones.\nThe partnership not only brings substantial non-dilutive funding to Nurix but also pairs its lead asset with Roche’s global development and commercialization capabilities...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-is-up-305-after-landmark-roche-btk-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-is-up-305-after-landmark-roche-btk-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LARK","NRIX","BK4139","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646812023","title":"Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 28,935 Common Shares for $580,006","url":"https://stock-news.laohu8.com/highlight/detail?id=2646812023","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646812023?lang=en_us&edition=fundamental","pubTime":"2026-06-26 06:38","pubTimestamp":1782427133,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring disposes of 28,935 common shares for $580,006Nurix Therapeutics Chief Legal Officer Christine Ring sold 28,935 common shares on June 25, 2026 at U","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDL38jxrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 28,935 Common Shares for $580,006","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644086453","title":"Nurix Therapeutics Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2644086453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644086453?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:11","pubTimestamp":1781788260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 09:11 ET (13:11 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644877042","title":"U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis","url":"https://stock-news.laohu8.com/highlight/detail?id=2644877042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644877042?lang=en_us&edition=fundamental","pubTime":"2026-06-18 15:14","pubTimestamp":1781766857,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Datadog, Jabil, PrologisJune 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, Jabil an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nL4N42Q0IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","FR","ESS","LU0342679015.USD","LXP","CAG","MUU","BIIB","GRDN","MULL","PAYO","INDV","JBL","HIMY","BTSG","DDOG","NRIX","TXG","PEP","LU1861215975.USD","LU2236285917.USD","EFX","BDSX","CME","BXP","FROG","INTU","LU2211815571.USD","NUE","MUD","KMX","HIMS","MU","HIMZ","AJG","PK","EGP","EFSC","AHR","ILMN","EXR","HIYY","CPT","EPRT","TECH","ANDE","DUK","DOGD","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201715","title":"Stifel Nicolaus Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201715","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643201715?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:37","pubTimestamp":1781534231,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics today and set a price target of $34.00. Willey covers the Heal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643710201","title":"Jefferies Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643710201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643710201?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:19","pubTimestamp":1781533158,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song maintained a Buy rating on Nurix Therapeutics today and set a price target of $45.00. Song covers the Healthcare secto...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-their-buy-rating-for-nurix-therapeutics-nrix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203034","title":"Nurix Therapeutics Price Target Maintained With a $34.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203034?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:26","pubTimestamp":1781526360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 08:26 ET (12:26 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642258292","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2642258292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642258292?lang=en_us&edition=fundamental","pubTime":"2026-06-12 08:20","pubTimestamp":1781223613,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX), DENTSPLY SIRONA (XRAY) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-220?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-220?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","XRAY","BK4139","BK4585","BK4198","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286211","title":"Nurix reports 22.1-month median PFS in Phase 1a trial of BTK degrader bexobrutideg for relapsed/refractory CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286211","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286211?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:02","pubTimestamp":1781175732,"startTime":"0","endTime":"0","summary":"Nurix flagged updated Phase 1a/b results for bexobrutideg, a BTK degrader for CLL/SLL, scheduled for presentation at the 2026 EHA Congress.Heavily pretreated relapsed or refractory patients showed durable responses, supporting continued development despite prior exposure to multiple standard therapies.Earlier-line cohorts showed strong anti-tumor activity, including patients who had progressed on a BTK inhibitor but had not used a BCL2 inhibitor.The safety profile remained broadly consistent with prior disclosures, with tolerability supporting longer treatment duration and expansion into broader studies.Nurix said the readout underpins plans for a broad Phase 3 monotherapy program, with combination regimens also under evaluation alongside a Roche collaboration.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL4g6mRm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","SG9999014013.SGD","SG9999014039.USD","NDAQ","BK4139","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","NRIX","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642861872","title":"Nurix Therapeutics - Reports 92.9% Objective Response Rate in Second Line Btki-Exposed, Bcl2i-NaÏVe Cll Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642861872","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642861872?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA3LQJZQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642828649","title":"Nurix Therapeutics - Responses Observed in High-Risk, Btk Resistant, and CNS-Involved Cll Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2642828649","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642828649?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA3LQJZQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642328619","title":"Nurix Therapeutics - Phase 1a Data Shows 22.1 Month Median Pfs, 83% Orr in Heavily Pretreated Relapsed/Refractory Cll/Sll","url":"https://stock-news.laohu8.com/highlight/detail?id=2642328619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642328619?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA3LQJZQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286467","title":"Nurix Therapeutics - Bexobrutideg Well Tolerated With Consistent Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286467?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA3LQJZQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642157286","title":"Nurix Therapeutics to Report Updated Phase 1a/B Results for Btk Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory Cll/Sll and Promising Activity in Earlier Lines of Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2642157286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642157286?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA3LQJZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423496","title":"Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423496?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:42","pubTimestamp":1781091720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2026 07:42 ET (11:42 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642446184","title":"Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642446184?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:20","pubTimestamp":1781000415,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Edwards Lifesciences (EW), Nurix Therapeutics (NRIX)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-edwards-lifesciences-ew-nurix-therapeutics-nrix-and-gilead-sciences-gild-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-edwards-lifesciences-ew-nurix-therapeutics-nrix-and-gilead-sciences-gild-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BSNM7G36.USD","LU0289739699.SGD","LU1585245621.USD","BK4585","SG9999001176.USD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU1023059063.AUD","GILD","LU1571399168.USD","LU1057294990.SGD","BK4567","LU2112291526.USD","HCSG","IE00B19Z3581.USD","IE00BN0W2W23.USD","LU0861579265.USD","BK4568","LU0965509283.SGD","BK4566","LU0345774391.USD","LU2089984988.USD","IE00BFXG0V08.USD","LU0029874061.USD","LU1061106388.HKD","NRIX","LU1934455194.USD","LU0882574055.USD","SG9999015986.USD","LU2468319806.SGD","LU2324357040.USD","LU0234570918.USD","SG9999015978.USD","BK4581","BK4504","LU1934455277.USD","XLV","BK4139","IE00B19Z3B42.SGD","XBI","IE00B3T34201.USD","IE0002270589.USD","LU1674673691.USD","SG9999001176.SGD","LABU","LU1674673428.USD","EW","LU1839511570.USD","LU1037948541.HKD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642361334","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Nurix Therapeutics (NRIX) and Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642361334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642361334?lang=en_us&edition=fundamental","pubTime":"2026-06-09 02:10","pubTimestamp":1780942220,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nurix Therapeutics (NRIX) and Incyte (INCY). Nurix Therapeutics (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nurix-therapeutics-nrix-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nurix-therapeutics-nrix-and-incyte-incy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4550","BK4585","BK4588","LU0128526141.USD","BK4532","LABU","BK4139","BK4581","HCSG","NRIX","LU0029874061.USD","XLV","INCY","XBI","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642761435","title":"Nurix Therapeutics price target raised to $45 from $41 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2642761435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642761435?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:31","pubTimestamp":1780939863,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song raised the firm’s price target on Nurix Therapeutics (NRIX) to $45 from $41 and keeps a Buy rating on the shares after...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-price-target-raised-to-45-from-41-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-price-target-raised-to-45-from-41-at-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641743336","title":"Nurix Therapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2641743336","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641743336?lang=en_us&edition=fundamental","pubTime":"2026-06-08 23:57","pubTimestamp":1780934220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 11:57 ET (15:57 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":0.2788},{"period":"1month","weight":0.3429},{"period":"3month","weight":0.5387},{"period":"6month","weight":0.2572},{"period":"1year","weight":1.049},{"period":"ytd","weight":0.2572}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.1394},{"period":"6month","weight":0.0866},{"period":"1year","weight":0.2051},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.5,"avgChangeRate":0.009892},{"month":6,"riseRate":0.666667,"avgChangeRate":0.155538},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}